艾迪注射液辅助治疗卵巢癌的疗效及对肿瘤标志物的影响

Efficacy of adjuvant Aidi injection for ovarian cancer and its effect on tumor marker

目的探讨艾迪注射液辅助治疗卵巢癌的疗效及对肿瘤标志物的影响。方法将108例卵巢癌患者按照治疗方式的不同分为化疗组和联合组,每组54例。化疗组患者采用常规化疗,联合组患者在化疗组基础上加用艾迪注射液。比较两组患者治疗后临床疗效,治疗前后血清糖类抗原19-9、糖类抗原125、癌胚抗原(CEA)、血管内皮生长因子(VEGF)水平,T细胞亚群水平以及不良反应发生情况。结果联合组患者总缓解率高于化疗组,差异有统计学意义(P﹤0.05)。治疗后,两组患者糖类抗原19-9、糖类抗原125、CEA、VEGF水平均降低,且联合组患者糖类抗原19-9、糖类抗原125、CEA、VEGF水平均低于化疗组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)、CD8^(+)水平均降低,但联合组患者CD3^(+)、CD4^(+)、CD8^(+)水平均高于化疗组,差异均有统计学意义(P﹤0.05)。联合组患者不良反应总发生率低于化疗组,差异有统计学意义(P﹤0.05)。结论艾迪注射液辅助治疗卵巢癌可有效降低肿瘤标志物水平,改善免疫功能,降低不良反应发生率,疗效确切。

Objective To investigate the efficacy of adjuvant Aidi injection for ovarian cancer patients and its effect on tumor markers.Method A total of 108 patients with ovarian cancer were divided into chemotherapy group and com-bination group according to different treatment methods,with 54 cases in each group.The patients in the chemotherapy group received conventional chemotherapy,and the patients in the combination group received Aidi injection based on the fundamental chemotherapy regimen.The clinical efficacy,serum carbohydrate antigen 19-9,carbohydrate antigen 125,carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)levels,T cell subset levels before and after the treatment,and adverse events of the two groups were compared.Result The overall response rate of patients in the combination group was higher than that in the chemotherapy group,and the difference was statistically significant(P<0.05).After the treatment,the levels of carbohydrate antigen 19-9,carbohydrate antigen 125,CEA,and VEGF in the two groups were decreased,and the levels of carbohydrate antigen 19-9,carbohydrate antigen 125,CEA,and VEGF in the combination group were lower than those in the chemotherapy group,the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+),and CD8^(+)in the two groups were decreased,but the levels of CD3^(+),CD4^(+),and CD8^(+)in the combination group were higher than those in the chemotherapy group,and the differences were sta-tistically significant(P<0.05).The total incidence of adverse events in the combination group was lower than that in the chemotherapy group,and the difference was statistically significant(P<0.05).Conclusion Adjuvant Aidi injection for ovarian cancer,whose effect is definite,could effectively reduce the level of tumor markers,improve patients’immune function,and reduce the incidence of adverse events.